Nuveen Asset Management, LLC Krystal Biotech, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 311,855 shares of KRYS stock, worth $55.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

311,855

Previous 336,170 7.23%

Holding current value

$55.5 Million

Previous $61.7 Million 8.14%

% of portfolio

0.02%

Previous 0.02%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $4.25 Million - $5.2 Million	-24,315 Reduced 7.23%	311,855 $56.7 Million
Q2 2024 Aug 09, 2024	BUY	$153.12 - $183.64 $877,071 - $1.05 Million	5,728 Added 1.73%	336,170 $61.7 Million
Q1 2024 May 13, 2024	BUY	$108.01 - $179.35 $1.62 Million - $2.69 Million	14,977 Added 4.75%	330,442 $58.8 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $5.11 Million - $6.83 Million	53,231 Added 20.3%	315,465 $39.1 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $12.1 Million - $14.5 Million	111,395 Added 73.85%	262,234 $30.4 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $7.68 Million - $12.8 Million	97,908 Added 184.97%	150,839 $17.7 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $324,379 - $377,613	-4,481 Reduced 7.8%	52,931 $4.24 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $1.76 Million - $2.23 Million	-27,913 Reduced 32.71%	57,412 $4.55 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $2,010 - $2,554	-31 Reduced 0.04%	85,325 $5.95 Million
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $53,676 - $80,596	1,097 Added 1.3%	85,356 $5.6 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $316,151 - $438,500	6,081 Added 7.78%	84,259 $5.64 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $164,096 - $363,725	-4,122 Reduced 5.01%	78,178 $5.47 Million
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $732,820 - $1.01 Million	14,090 Added 20.66%	82,300 $4.3 Million
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $988,895 - $1.3 Million	15,914 Added 30.43%	68,210 $4.64 Million
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $243,919 - $350,813	4,105 Added 8.52%	52,296 $4.03 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $49,458 - $74,699	1,217 Added 2.59%	48,191 $2.89 Million
Q3 2020 Nov 16, 2020	BUY	$37.76 - $48.49 $104,746 - $134,511	2,774 Added 6.28%	46,974 $2.02 Million
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $93,463 - $151,440	2,524 Added 6.06%	44,200 $1.83 Million
Q1 2020 May 14, 2020	BUY	$35.02 - $65.64 $76,658 - $143,685	2,189 Added 5.54%	41,676 $1.8 Million
Q4 2019 Feb 14, 2020	SELL	$33.17 - $65.23 $37,979 - $74,688	-1,145 Reduced 2.82%	39,487 $2.19 Million
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $189,224 - $279,585	5,450 Added 15.49%	40,632 $1.41 Million
Q2 2019 Aug 15, 2019	BUY	$27.2 - $41.2 $956,950 - $1.45 Million	35,182 New	35,182 $1.42 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Krystal Biotech, Inc. Transaction History